Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
BBO-8520 by BridgeBio Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
BBO-8520 is under clinical development by BridgeBio Pharma and currently in Phase I for Non-Small Cell Lung Cancer. According to...